Apimeds Pharmaceuticals US, Inc (APUS) Financial Ratios
5 years of historical data (2021–2025) · Healthcare · Drug Manufacturers - Specialty & Generic
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
0.00
↓-14% vs avg
5yr avg: 0.00
30Y Low0.0·High0.0
ROE
↑
-7.8%
↓+99% vs avg
5yr avg: -1224.0%
30Y Low-8%·High-8%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
APUS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Apimeds Pharmaceuticals US, Inc currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $16M | $18M | — | — | — | — |
| Enterprise Value | $6.2B | $6.2B | — | — | — | — |
| P/E Ratio → | -2.67 | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — |
| P/B Ratio | 0.00 | 0.00 | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
APUS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
APUS Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -7.8% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| Net Profit Margin | — | — | — | — | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | -7.8% | -7.8% | — | -2440.1% | — | — |
| ROA | -7.3% | -7.3% | -638.9% | -363.2% | -749.9% | -596.1% |
| ROIC | -0.0% | -0.0% | — | — | — | — |
| ROCE | -0.0% | -0.0% | — | -250.2% | — | -631.2% |
APUS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $6.1B ($7.8B total debt minus $1.6B cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.05 | 0.05 | — | 8.37 | — | — |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.04 | — | -4.51 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -42.09 | -42.09 | -10.81 | -19.43 | -21.95 | -151.26 |
APUS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.31x means Apimeds Pharmaceuticals US, Inc can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 3.42x to 1.31x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 1.31 | 1.31 | 0.01 | 3.42 | 0.02 | 16.16 |
| Quick Ratio | 1.31 | 1.31 | 0.01 | 3.42 | 0.02 | 16.16 |
| Cash Ratio | 0.34 | 0.34 | 0.00 | 3.33 | 0.02 | 16.09 |
| Asset Turnover | — | — | — | — | — | — |
| Inventory Turnover | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — |
APUS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Apimeds Pharmaceuticals US, Inc does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $11M | $1M | $1M | $1M | $1M |
Peer Comparison
Compare APUS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 APUSYou | $16M | -2.7 | — | — | — | — | -7.8% | -0.0% | — |
 HALO | $8B | 25.5 | 8.3 | 11.9 | 78.1% | 58.4% | 153.6% | 73.4% | — |
 ACRS | $586M | -9.2 | — | — | 73.3% | -975.9% | -50.2% | -53.5% | — |
 SLRX | $697790 | -0.0 | — | — | — | — | -164.0% | — | — |
 NUVB | $2B | -8.0 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 PRGO | $2B | -1.1 | 7.4 | 11.1 | 35.1% | 8.1% | -39.3% | 3.7% | 5.8 |
 PAHC | $2B | 36.3 | 15.7 | 41.8 | 30.9% | 8.5% | 17.8% | 9.8% | 4.9 |
 CRL | $9B | -62.5 | 13.0 | 17.3 | 30.5% | 12.6% | -4.3% | 6.3% | 3.4 |
 IQV | $30B | 22.8 | 13.0 | 14.8 | 26.3% | 14.0% | 21.4% | 8.7% | 4.7 |
 MEDP | $12B | 28.1 | 21.3 | 18.0 | 30.1% | 21.1% | 70.2% | 154.9% | 0.4 |
 ICLR | $10B | 13.1 | 7.9 | 8.5 | 29.4% | 13.3% | 8.4% | 6.5% | 2.3 |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
See APUS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs APUS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare APUS vs HALO
Side-by-side business, growth, and profitability comparison vs Halozyme Therapeutics, Inc..
Start ComparisonAPUS — Frequently Asked Questions
Quick answers to the most common questions about buying APUS stock.
What is Apimeds Pharmaceuticals US, Inc's P/E ratio?
Apimeds Pharmaceuticals US, Inc's current P/E ratio is -2.7x. This places it at the 50th percentile of its historical range.
What is Apimeds Pharmaceuticals US, Inc's ROE?
Apimeds Pharmaceuticals US, Inc's return on equity (ROE) is -7.8%. The historical average is -7.8%.
Is APUS stock overvalued?
Based on historical data, Apimeds Pharmaceuticals US, Inc is trading at a P/E of -2.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.